Influence of cord blood serum and actovegin on the reproductive function of cows in the comparative aspect
The results of the study of the effect of cord blood serum and “Actovegin” (Takeda, Ukraine) on the reproductive function of cows in a comparative aspect are presented.
The aim of the study was to analyze the effect of cord blood serum and Actovegin on the reproductive function of uterine cows in a comparative aspect.
Materials and methods. The research was conducted during 2017-2020 in four dairy farms of Sumy region with tethered and untied maintenance. In 128 cows of different breeds and productivity, the timing of sexual cycling was studied and analyzed in comparison with the spontaneous sexual cycle with the use of cord blood serum and the drug "Actovegin" (Takeda, Ukraine).
Results. It was found that in cows with tethered content, the number of days from the introduction of 15 ml of cord blood serum to the manifestation of the excitation stage was significantly less compared to the spontaneous manifestation of sexual desire (5.63±0.36 and 14.38±2.1, respectively).
When cows with loose content were administered 10 ml of cord blood serum in combination with the drug "Actovegin", the number of days before the manifestation of sexual cycling was lower by 18.3 % compared with the rate of spontaneous sexual desire (4.31±0.38 and 18.25±1.89, respectively).
Conclusions. As a result of using 10 ml of cord blood serum in combination with the drug "Actovegin", in cows of different productivity and under different housing conditions, the number of days before the onset of the stage of arousal is significantly reduced compared to the spontaneous manifestation of sexual desire.
Cows of different productivity and with different housing conditions come to the sexual desire significantly faster with the use of 15 ml of cord blood serum compared to the spontaneous manifestation of sexual desire.
Yan, T., Venkat, P., Chopp, M., Zacharek, A., Ning, R., Cui, Y. et. al. (2015). Neurorestorative Therapy of Stroke in Type 2 Diabetes Mellitus Rats Treated With Human Umbilical Cord Blood Cells. Stroke, 46 (9), 2599–2606. doi: http://doi.org/10.1161/strokeaha.115.009870
Buchmayer, F., Pleiner, J., Elmlinger, M. W., Lauer, G., Nell, G., Sitte, H. H. (2011). Actovegin®: a biological drug for more than 5 decades. Wiener Medizinische Wochenschrift, 161 (3-4), 80–88. doi: http://doi.org/10.1007/s10354-011-0865-y
Panossian, A., Seo, E.-J., Efferth, T. (2019). Effects of anti-inflammatory and adaptogenic herbal extracts on gene expression of eicosanoids signaling pathways in isolated brain cells. Phytomedicine, 60, 152881. doi: http://doi.org/10.1016/j.phymed.2019.152881
Sun, J., Wang, J., Pefanis, E., Chao, J., Rothschild, G., Tachibana, I. et. al. (2015). Transcriptomics Identify CD9 as a Marker of Murine IL-10-Competent Regulatory B Cells. Cell Reports, 13 (6), 1110–1117. doi: http://doi.org/10.1016/j.celrep.2015.09.070
Zhang, J., Lv, S., Liu, X., Song, B., Shi, L. (2018). Umbilical cord mesenchymal stem cell treatment for crohn’s disease: a randomized controlled clinical trial. Gut Liver, 12, 73–78. doi: http://doi.org/10.5009/gnl17035
Wu, M., Zhang, R., Zou, Q., Chen, Y., Zhou, M., Li, X. et. al. (2018). Comparison of the Biological Characteristics of Mesenchymal Stem Cells Derived from the Human Placenta and Umbilical Cord. Scientific Reports, 8 (1). doi: http://doi.org/10.1038/s41598-018-23396-1
Van Pham, P., Dang, L. T.-T., Dinh, U. T., Truong, H. T.-T., Huynh, B. N., Van Le, D., Phan, N. K. (2013). In vitro evaluation of the effects of human umbilical cord extracts on human fibroblasts, keratinocytes, and melanocytes. In Vitro Cellular & Developmental Biology – Animal, 50 (4), 321–330. doi: http://doi.org/10.1007/s11626-013-9706-1
Brock, J., Golding, D., Smith, P. M., Nokes, L., Kwan, A., Lee, P. Y. F. (2018). Update on the Role of Actovegin in Musculoskeletal Medicine. Clinical Journal of Sport Medicine, 30 (1), 83–90. doi: http://doi.org/10.1097/jsm.0000000000000566
Lee, P., Kwan, A., Nokes, L. (2011). Actovegin® – Cutting-edge Sports Medicine or “Voodoo” Remedy? Current Sports Medicine Reports, 10 (4), 186–190. doi: http://doi.org/10.1249/jsr.0b013e318223cd8a
Riordan, N. H., Morales, I., Fernández, G., Allen, N., Fearnot, N. E., Leckrone, M. E. et. al. (2018). Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis. Journal of Translational Medicine, 16 (1). doi: http://doi.org/10.1186/s12967-018-1433-7
Ren, H., Sang, Y., Zhang, F., Liu, Z., Qi, N., Chen, Y. (2016). Comparative Analysis of Human Mesenchymal Stem Cells from Umbilical Cord, Dental Pulp, and Menstrual Blood as Sources for Cell Therapy. Stem Cells International, 2016, 1–13. doi: http://doi.org/10.1155/2016/3516574
Mann, L., Snowise, S., Morales, Y., Prabhu, S., Tseng, S., Grill, R. et. al. (2016). Neurological Outcomes after Human Umbilical Cord Patch for In Utero Spina Bifida Repair in a Sheep Model. American Journal of Perinatology Reports, 6 (3), e309–e317. doi: http://doi.org/10.1055/s-0036-1592316
Kuchma, M. D., Kyryk, V. M., Svitina, H. M., Shablii, Y. M., Lukash, L. L., Lobyntseva, G. S., Shablii, V. A. (2015). Comparative Analysis of the Hematopoietic Progenitor Cells from Placenta, Cord Blood, and Fetal Liver, Based on Their Immunophenotype. BioMed Research International, 2015, 1–16. doi: http://doi.org/10.1155/2015/418752
Pittenger, M. F., Discher, D. E., Péault, B. M., Phinney, D. G., Hare, J. M., Caplan, A. I. (2019). Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regenerative Medicine, 4 (1). doi: http://doi.org/10.1038/s41536-019-0083-6
Nagaishi, K., Mizue, Y., Chikenji, T., Otani, M., Nakano, M., Saijo, Y. et. al. (2017). Umbilical cord extracts improve diabetic abnormalities in bone marrow-derived mesenchymal stem cells and increase their therapeutic effects on diabetic nephropathy. Scientific Reports, 7 (1). doi: http://doi.org/10.1038/s41598-017-08921-y
McLaughlin, C. A., West, T., Hollowell, R., Skergan, N. N., Baker, J., Donner, H. et. al. (2019). Expanded Access Protocol of Umbilical Cord Blood Infusion for Children with Neurological Conditions. STEM CELLS Translational Medicine, 8 (S1). doi: http://doi.org/10.1002/sctm.12583
Marston, W. A., Lantis, J. C., Wu, S. C., Nouvong, A., Lee, T. D., McCoy, N. D. et. al. (2019). An open‐label trial of cryopreserved human umbilical cord in the treatment of complex diabetic foot ulcers complicated by osteomyelitis. Wound Repair and Regeneration, 27 (6), 680–686. doi: http://doi.org/10.1111/wrr.12754
Kočí, Z., Výborný, K., Dubišová, J., Vacková, I., Jäger, A., Lunov, O. et. al. (2017). Extracellular Matrix Hydrogel Derived from Human Umbilical Cord as a Scaffold for Neural Tissue Repair and Its Comparison with Extracellular Matrix from Porcine Tissues. Tissue Engineering Part C: Methods, 23 (6), 333–345. doi: http://doi.org/10.1089/ten.tec.2017.0089
Ferdous, K. M. N. U., Hasan, M. S., Kabir, K. A., Zahid, M. K., Islam, M. K., Hasanuzzaman, M. (2018). Use of Umbilical Cord flap for Closure of Gastroschisis. Journal of Shaheed Suhrawardy Medical College, 10 (1), 47–50. doi: http://doi.org/10.3329/jssmc.v10i1.38904
Yamamoto, E., Niimi, K., Fujikake, K., Nishida, T., Murata, M., Mitsuma, A. et. al. (2016). High-dose chemotherapy with autologous peripheral blood stem cell transplantation for choriocarcinoma: A case report and literature review. Molecular and Clinical Oncology, 5 (5), 660–664. doi: http://doi.org/10.3892/mco.2016.1011
Doi, H., Kitajima, Y., Luo, L., Yan, C., Tateishi, S., Ono, Y. et. al. (2016). Potency of umbilical cord blood- and Wharton’s jelly-derived mesenchymal stem cells for scarless wound healing. Scientific Reports, 6 (1). doi: http://doi.org/10.1038/srep18844
Couto, P. S., Shatirishvili, G., Bersenev, A., Verter, F. (2019). First decade of clinical trials and published studies with mesenchymal stromal cells from umbilical cord tissue. Regenerative Medicine, 14 (4), 309–319. doi: http://doi.org/10.2217/rme-2018-0171
Copyright (c) 2021 Irina Bondarenko, Andrey Lazorenko, Oksana Shkromada
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.